Basilea Pharmaceutica AG Cash Flow-to-Debt Ratio
Basilea Pharmaceutica AG cash flow-to-debt ratio. Basilea Pharmaceutica AG (BSLN) has a Cash Flow-to-Debt Ratio of 0.25x as of December 2025, meaning its operating cash flow of CHF39.03 Million could theoretically repay 0% of its total liabilities (CHF154.06 Million) in one year. Check Basilea Pharmaceutica AG (BSLN) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Basilea Pharmaceutica AG (2002–2025)
Cash flow-to-debt ratio of Basilea Pharmaceutica AG from 2002 to 2025. Historical debt coverage capacity for Basilea Pharmaceutica AG across 24 annual periods. Check BSLN cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Basilea Pharmaceutica AG Cash Flow-to-Debt Ratio by Year (2002–2025)
Basilea Pharmaceutica AG cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for Basilea Pharmaceutica AG. For the full cash flow conversion analysis, see Basilea Pharmaceutica AG (BSLN) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (CHF) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.40x | CHF62.09 Million | CHF154.06 Million | ▼ -4.2% |
| 2024 | 0.42x | CHF74.36 Million | CHF176.76 Million | ▲ +441.3% |
| 2023 | 0.08x | CHF14.24 Million | CHF183.29 Million | ▲ +166.1% |
| 2022 | 0.03x | CHF7.06 Million | CHF241.56 Million | ▲ +127.9% |
| 2021 | -0.10x | CHF-32.02 Million | CHF305.87 Million | ▲ +35.8% |
| 2020 | -0.16x | CHF-54.13 Million | CHF331.84 Million | ▲ +19.6% |
| 2019 | -0.20x | CHF-63.84 Million | CHF314.43 Million | ▲ +10.7% |
| 2018 | -0.23x | CHF-79.21 Million | CHF348.44 Million | ▼ -569.4% |
| 2017 | 0.05x | CHF19.01 Million | CHF392.61 Million | ▲ +123.4% |
| 2016 | -0.21x | CHF-75.00 Million | CHF362.76 Million | ▼ -17.1% |
| 2015 | -0.18x | CHF-67.78 Million | CHF383.88 Million | ▲ +50.7% |
| 2014 | -0.36x | CHF-71.46 Million | CHF199.45 Million | ▼ -37.9% |
| 2013 | -0.26x | CHF-59.47 Million | CHF228.88 Million | ▼ -147.3% |
| 2012 | 0.55x | CHF148.17 Million | CHF269.84 Million | ▲ +155.9% |
| 2011 | -0.98x | CHF-82.38 Million | CHF83.82 Million | ▼ -198.0% |
| 2010 | 1.00x | CHF106.64 Million | CHF106.30 Million | ▲ +195.4% |
| 2009 | -1.05x | CHF-114.51 Million | CHF108.88 Million | ▼ -6.2% |
| 2008 | -0.99x | CHF-127.17 Million | CHF128.38 Million | ▼ -58.4% |
| 2007 | -0.63x | CHF-78.99 Million | CHF126.34 Million | ▲ +21.7% |
| 2006 | -0.80x | CHF-72.47 Million | CHF90.78 Million | ▼ -303.6% |
| 2005 | 0.39x | CHF34.38 Million | CHF87.69 Million | ▲ +112.9% |
| 2004 | -3.03x | CHF-64.20 Million | CHF21.18 Million | ▲ +3.3% |
| 2003 | -3.13x | CHF-52.42 Million | CHF16.73 Million | ▼ -22.9% |
| 2002 | -2.55x | CHF-64.07 Million | CHF25.13 Million | — |